FDA Declines Approval of China-Developed Lung Cancer Drug After Survival Goal Missed
The FDA declined to approve Akeso's lung cancer drug ivonescimab, developed with Summit Therapeutics, due to insufficient evidence of improved survival in trials. The drug delayed cancer progression but did not meet statistical survival requirements. Summit plans further trials, and Akeso retains rights in China. AstraZeneca invested $2B in Summit for ivonescimab's development.
How this was made

The 30-second read
Why it matters
The FDA declined approval because the HARMONi trial did not establish a statistically significant overall-survival improvement, despite favorable medians for progression-free timing and overall survival.
Market read
A U.S. regulatory denial for a lead oncology asset is a high-impact catalyst that can reprice approval probability, development timelines, and partner/investor expectations.
What to watch
The article notes longer follow-up analyses were not persuasive to the FDA, but it does not quantify how much additional follow-up could change statistical outcomes in the next trial, nor does it detail any planned protocol or endpoint adjustments for HARMONi-3.
Background
Ivonescimab (Akeso) is approved in China for certain advanced lung cancer settings and had earlier international attention from a China-only trial (HARMONi-2) versus Merck’s Keytruda; the FDA decision concerns a separate international Phase III trial (HARMONi).
Ticker impact
Summit Therapeutics’ FDA submission for ivonescimab plus chemotherapy was rejected in its current form after the HARMONi Phase III trial failed to show statistically significant overall-survival improvement.
Likely pressure as the market discounts U.S. approval odds for the current regimen and focuses on the next trial path (HARMONi-3).
The article ties the rejection directly to Summit’s application and cites the FDA’s stated requirement for statistically significant overall survival.
Market effects
Highlights heightened FDA evidentiary thresholds for oncology survival endpoints and the market’s sensitivity to trial-readout statistical significance.
Reinforces U.S. scrutiny of foreign clinical-trial data, potentially affecting sentiment toward other China-developed oncology programs seeking U.S. approval.
May influence global biotech risk models for cross-border development and the perceived approval pathway for China-origin assets in the U.S.
Counterpoint
The rejection is for the current HARMONi regimen and evidence set; Summit is already pursuing HARMONi-3, which could produce a different comparative design and survival readout.
Key entities
- companyAkeso
China-developed ivonescimab; FDA non-approval in the U.S. is a direct negative for its global development value.
- companySummit Therapeutics
U.S. licensee that filed the FDA application and received the response letter declining approval in its current form.
- regulatorFDA
Issued a response letter stating the application could not be approved due to insufficient overall-survival evidence.
- companyAstraZeneca
Completed a $2 billion investment in Summit to support further development of ivonescimab.



